Compare CSTL & SPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSTL | SPFI |
|---|---|---|
| Founded | 2007 | 1941 |
| Country | United States | United States |
| Employees | N/A | 603 |
| Industry | Medical Specialities | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 843.2M |
| IPO Year | 2019 | 2019 |
| Metric | CSTL | SPFI |
|---|---|---|
| Price | $32.37 | $44.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $45.50 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 310.1K | 82.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.68% |
| EPS Growth | N/A | ★ 17.81 |
| EPS | N/A | ★ 1.82 |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | $22.65 |
| Revenue Next Year | $12.69 | $9.40 |
| P/E Ratio | ★ N/A | $24.73 |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $17.72 | $35.34 |
| 52 Week High | $44.28 | $46.94 |
| Indicator | CSTL | SPFI |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 48.92 |
| Support Level | $22.88 | $44.05 |
| Resistance Level | $34.23 | $45.40 |
| Average True Range (ATR) | 1.54 | 0.82 |
| MACD | -0.42 | 0.05 |
| Stochastic Oscillator | 23.40 | 52.18 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.